An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer

Abstract Dexamethasone has antitumor activity in metastatic castration resistant prostate cancer (mCRPC). We aimed to investigate intravenous liposome‐encapsulated dexamethasone disodium phosphate (liposomal dexamethasone) administration in mCRPC patients. In this exploratory first‐in‐man study, pat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Josephina P. M. Vrouwe, Ingrid M. C. Kamerling, Michiel J. vanEsdonk, Josbert M. Metselaar, Frederik E. Stuurman, Gabri van derPluijm, Jacobus Burggraaf, Susanne Osanto
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Acceso en línea:https://doaj.org/article/7f6f12eb65c74ad0b8cee9f1481033da
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!